Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling

Open access
De Sousa Linhares, Annika, Battin, Claire, Jutz, Sabrina, Leitner, Judith, Hafner, Christine, Tobias, Joshua, Wiedermann, Ursula, Kundi, Michael, Zlabinger, Gerhard J., Grabmeier-Pfistershammer, Katharina, Steinberger, Peter·2019·Scientific Reports

Abstract

Inhibitors of PD-1 signaling have revolutionized cancer therapy. PD-1 and PD-L1 antibodies have been approved for the treatment of cancer. To date, therapeutic PD-1 inhibitors have not been compared in a functional assay. We used an efficient T cell reporter platform to evaluate the efficacy of five clinically used PD-1 inhibitors to block PD-1 signaling. The half maximal effective concentrations (EC 50) for nivolumab and pembrolizumab were 76.17 ng/ml (95% CI 64.95–89.34 ng/ml) and 39.90 ng/ml (34.01–46.80 ng/ml), respectively. The EC 50 values of the PD-L1 inhibitors were 6.46 ng/ml (5.48–7.61 ng/ml), 6.15 ng/ml (5.24–7.21 ng/ml) and 7.64 ng/ml (6.52–8.96 ng/ml) for atezolizumab, avelumab, and durvalumab, respectively. In conclusion, a functional assay evaluating antibodies targeting PD-1 inhibition in vitro revealed that pembrolizumab is a slightly more effective PD-1 blocker than nivolumab, and that PD-L1 antibodies are superior to PD-1 antibodies in reverting PD-1 signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-47910-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 179

Metadata

Authors
De Sousa Linhares, A., Battin, C., Jutz, S., Leitner, J., Hafner, C., Tobias, J., Wiedermann, U., Kundi, M., Zlabinger, G. J., Grabmeier-Pfistershammer, K., & Steinberger, P.
Venue
Scientific Reports
Published
2019-08-07
Volume
9
Issue
1
Pages
11472-11472
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2965639414
Cited by
179
References
5
FWCI
7.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. https://app.cochat.ai/papers/10.1038/s41598-019-47910-1
The paper
De Sousa Linhares, A., Battin, C., Jutz, S., Leitner, J., Hafner, C., Tobias, J., Wiedermann, U., Kundi, M., Zlabinger, G. J., Grabmeier-Pfistershammer, K., & Steinberger, P. (2019). Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Scientific Reports. https://doi.org/10.1038/s41598-019-47910-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.